Rational Pharmacotherapy in Cardiology

Advanced search

Transforming Growth Factor β1 and Myocardial Remodeling in Patients with Chronic Heart Failure of Ischemic Genesis

Full Text:


Aim. To study the presence and nature of correlations between the level of transforming growth factor β1 (TFR-β1) and structural and functional parameters of the heart in the development of myocardial remodeling and fibrosis in patients with chronic heart failure (CHF) of ischemic origin.

Material and methods. The study included 120 men with class II-IV CHF who have history of myocardial infarction, which are divided into 3 groups depending on the CHF class. The control group included 25 healthy men. Assessment of left ventricular (LV) structural-functional state was carried out by echocardiography. Investigation of TFR-β1 and N-terminal precursor indices of cerebral natriuretic peptide (NT-pro BNP) was performed by enzyme immunoassay.

Results. Patients with class II-IV CHF were hyperexpression of ТФР-β1, the levels of which increased significantly as NYHA class increased and CHF progressed. The most significant structural-geometric rearrangement of LV and hyperactivation ТФР-β1 recorded in patients with class IV CHF (77.2±6.33 ng/ml with class IV CHF versus 46.7±3.74 ng/ml and 58.9±4.75 ng/ml with class II and III CHF; р< 0.05). In patients of class III-IV CHF, correlation relationships between ТФР-β1 level and echocardiographic parameters (LV myocardial mass index are established: r = 0.56, p = 0.05; end systolic volume index: r = 0.52, p = 0.05; value of LV ejection fraction: r = -0.48, p=0,05). Significant direct relationships are established in patients with class III-IV CHF between ТФР-β1 level and NT-rgo BNP levels (r=0,44; р=0,05).

Conclusion. The intensity of myocardial remodeling and fibrosis processes in patients with a progressive course of CHF is related to ТФР-β1 hyperexpression and is associated with a high level of activity of natriuretic peptides.

About the Authors

N. E. Zakirova
Bashkir State Medical University
Russian Federation

Nelli E. Zakirova


eLibrary SPIN: 9132-7358

A. N. Zakirova
Bashkir State Medical University
Russian Federation

Alyara N. Zakirova


eLibrary SPIN: 2224-2179

D. F. Nizamova
Bashkir State Medical University
Russian Federation

Dinara F. Nizamova


eLibrary SPIN: 3869-5492


1. Mareev V.Y., Fomin I.V., Ageev F.T., et al. Heart failure: chronic (CHF) and acute decompensated (ODHF). Diagnosis, prevention and treatment. Kardiologia. 2018; 58 (36): 8-164. (In Russ) DOI:10.18087/cardio.2475.

2. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheart/ehw128.

3. Opie Z.H., Commerford E.J., Gerch B.J., Pfeffer M.A. Cotroversies in ventricular remodeling. Lancet. 2006;367(9507):356-67. DOI:10.1016/S0140-6736(06)68074-4

4. Zakirova N.E., Zakirova A.N. The role of immune inflammatory reactions and endothelial dysfunction in myocardial remodeling and progression of ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2014;10(5):488-94 (In Russ)

5. Kapelko V. I. Extracellular matrix of myocardium and heart disease. Kardiologiia. 2000;9:78-90 (In Russ.) DOI:10.18087/cardio.2020.6.n773.

6. Ena L.M., Bevzyuk L.V. The role of hemodynamic and humoral factors in the pathogenesis of myocardial fibrosis in elderly patients with hypertension and atrial fibrillation. Problems of Aging and Longevity. 2013;22(4):365-79(In Russ)

7. Weber K.T. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22(1):47-50. DOI:10.1097/00004872-200401000-00011.

8. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210. DOI:10.1002/path.2277.

9. Moiseyeva O.M., Lyasnikova Y.A., Semenova E.G., et al. Transforming growth factor-beta1 and markers of leukocytic activation in hypertensive disease. Arterial Hypertension. 2003;9(1):14-6 (In Russ.) DOI:10.18705/1607-419X-2003-9-1-14-16.

10. Shlyakhto E.V., ed. Pathological гemodeling of the myocardium: problems of hypertrophy, inflammation and fibrosis. Clinical and experimental cardiology. SPb.: Academic medical center; 2005 (In Russ)

11. Rosenkranz S. TGF-beta 1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63(3):423-32. DOI:10.1016/j.cardiores.2004.04.030.

12. Korzhenevskaya K.V., Gavrischeva N.A., Panov A.V., et al. Transforming growth factor-beta-1 by different clinical course of ischemic heart disease after coronary artery bypass grafting surgery. Medical Immunology. 2010;12(6):521-8 (In Russ)

13. Verrecchia F., Mauviel A. Transfoming growth factor-beta and fibrosis. World J Gastroenterol. 2007;47(8):13-18. DOI:10.3748/wjg.v13.i22.3056.

14. Klass B.R., Grobbelaar A.L., Rolfe K.J. Transforming growth factor-beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Poctgraduate Medical J. 2009;85:9-14. DOI:10.1136/pgmj.2008.069831.

15. Leack A. Potential therapeutic targets for cardiac fibrosis, TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibrosis activation. Cirs Res. 2010;106(11):1675-88. DOI:10.1161/CIRCRESAHA.110.217737.

16. Drapkina O.M., Dadayeva V.A. Role of transforming growth factor beta in development of fibrosis at chronic heart failure. Russian Medical News. 2013;8(4):13-7 (In Russ.)

17. Malev E.G., Zemtsovsky E.V.,Omelchenko M.Yu., Vasina L.V. The Role of Transforming Growth Factor-beta in the Pathogenesis of Mitral Valve Prolapse. Kardiologiia. 2012;12:34-9 (In Russ)

18. Mallat Z., Tedgui A. The role of transforming growth factor beta in at atherosclerosis: novel insights and future perspective. Curr Opin Lipidol. 2002;13(5):523-9. DOI:10.1097/00041433-200210000-00008.

19. Dixon D.L., Griggs K.M., Bersten A.D. De Pasquale C.G. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56(3):593-9. DOI:10.1016/j.cyto.2011.08.029.

20. Sadovoy V.I. Сorrelation of cardiac remodeling and serum levels of transforming growth factor-B, hepatocyte growth factor and С-reactive protein in the early post-infarction period Remove selected. Therapeutic Medico-Biological Bulletin. 2014;17(1):106-10 (In Russ.)

21. Lang R., Badano L.P., Mor-Avi V., et al. Recommendation of Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;28(1):1-39е14. DOI:10.10.16/j.echo.2014.10.003.

22. Кopyeva K.V., Teplyakov A.T., Grakova E.V., et al. The role of the new ST2 biomarker in assessing myocardial remodeling in patients with chronic heart failure of ischemic origin with preserved left ventricular ejection fraction. Kardiologiia. 2018;58(S10):33-43 (In Russ.) DOI:10.18087/cardio.2498.

23. Belovol A.N., Knyazeva I.I. Cellular, molecules and structural mechanisms of LV remodeling in heart failure. Practical Angiology. 2013;4(63):53-65 (In Russ.)

24. Cohn J.N., Ferrari R., Sharpe N., on Behalf of the International Forumon Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications:a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569-82. DOI:10.1016/s0735-1097(99)00630-0.

25. Agarwall I., Glazer N.I., Barasch E., et al. Fibrosis-relation biomarkersand incident cardiovascular disease in older adults: the cardiovascular health Study. Cur Arrhythm Electrophysiol. 2014;7(4):583- 4. DOI:10.1161/CIRCEP.114.001610.

26. Seeland U., Schäffer A., Selejan S., et al. Effects of AT II and beta-adrenergie receptor antagonists on IGF-beta 1 - unduced fibrosis in trancgenic mice. Eur J Clin Investr. 2009;39(10):851-9. DOI:10.1111/j.1365-2362.2009.02183.x.

For citation:

Zakirova N.E., Zakirova A.N., Nizamova D.F. Transforming Growth Factor β1 and Myocardial Remodeling in Patients with Chronic Heart Failure of Ischemic Genesis. Rational Pharmacotherapy in Cardiology. 2021;17(1):36-41. (In Russ.)

Views: 101

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)